Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 9/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | ABL2 | P42684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21610146 | 0.83 | ALDH1A1 (0.40) | — | |
| SCHEMBL21610241 | 0.80 | DRD1 (0.38) | EGFRKDR | |
| SCHEMBL21610166 | 0.80 | KEAP1 (0.36) | GRM2KEAP1NFE2L2 | |
| SCHEMBL21610202 | 0.77 | HAO1 (0.35) | — | |
| SCHEMBL21610170 | 0.77 | HAO1 (0.47) | — | |
| SCHEMBL21610164 | 0.76 | KDR (0.36) | KDR | |
| SCHEMBL21610192 | 0.75 | NPC1 (0.37) | EGFR | |
| SCHEMBL21610231 | 0.74 | SMN1; SMN2 (0.37) | KDR | |
| SCHEMBL21610256 | 0.73 | MAP4K4 (0.40) | EGFRKDR | |
| SCHEMBL21610144 | 0.73 | RAF1 (0.39) | RETEGFRKDRABL1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3947365-B1 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LTD (AU) | 2025-10-01 | — | — | EP | disclosed |
| US-12139473-B2 | Substituted-N-heteroaryl compounds and uses thereof | BIONOMICS LIMITED (AU) | 2024-11-12 | — | — | US | disclosed |
| US-20220112176-A1 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2022-04-14 | — | — | US | disclosed |
| US-20220112176-A1 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2022-04-14 | — | — | US | disclosed |
| EP-3947365-A2 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | Bionomics Limited (AU) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020000065-A2 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2020-01-02 | — | — | WO | disclosed |
| WO-2020000065-A2 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2020-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112176-A1 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | GABRE, GRIN2C, GRIN2A | RET 2266/4885EGFR 4104/4885GRM2 42/4885 |
| US-12139473-B2 | Substituted-N-heteroaryl compounds and uses thereof | SCN3A, KCND3, GRIN3A | RET 1436/4885EGFR 4143/4885GRM2 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.